Share
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Manage episode 480134604 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In today’s episode, we had the pleasure of speaking with Jacob Moyer, BS, and Mark Tyson II, MD, MPH, about a real-world study investigating nadofaragene firadenovec in patients with BCG-unresponsive NMIBC. Moyer is a graduate researcher at Mayo Clinic in Scottsdale, Arizona. Tyson is a urologic oncologist and an associate professor of urology at the Mayo Clinic Alix School of Medicine in Arizona.
In our exclusive interview, Moyer and Tyson discussed the durable responses achieved with nadofaragene firadenovec in this patient population, the safety profile of this agent, the importance of pretreatment with antispasmodic medication, and the optimal patient population to receive nadofaragene firadenovec.
In our exclusive interview, Moyer and Tyson discussed the durable responses achieved with nadofaragene firadenovec in this patient population, the safety profile of this agent, the importance of pretreatment with antispasmodic medication, and the optimal patient population to receive nadofaragene firadenovec.
642 episodes
))
